BioNTech (BNTX) is trading lower after reporting first-quarter 2026 results that came in meaningfully below top-line expectations. Revenue was €118.1 million versus a €185.6 million consensus figure highlighted by earnings feeds, while losses widened as the company continued to fund late-stage oncology and antibody-drug conjugate programs. (streetinsider.com)

BioNTech reported a Q1 2026 net loss of €531.9 million (adjusted net loss €494.6 million) with diluted loss per share of €2.10 (adjusted €1.95). Management attributed the year-over-year revenue decline primarily to lower COVID-19 vaccine revenues, while R&D expense rose to €557.0 million as development work expanded across immuno-oncology and ADC programs and as acquired entities were integrated. (globenewswire.com)

BioNTech reaffirmed its full-year 2026 revenue guidance range of €2.0–€2.3 billion, keeping the near-term financial trajectory anchored to a lower-COVID baseline while spending remains heavy. The company also said it plans a share repurchase program of up to $1.0 billion in ADSs over the next 12 months, but the market reaction suggests investors are prioritizing the near-term revenue reset and loss profile over the buyback headline. (globenewswire.com)

Investors are likely to focus on whether upcoming late-stage oncology data readouts can de-risk the pipeline and improve the visibility of a path from R&D-heavy quarters to commercialization. BioNTech described 2026 as a catalyst-rich year with multiple expected late-stage readouts across immunomodulators, ADCs, and mRNA cancer immunotherapies, making upcoming clinical updates the next major driver for the stock. (globenewswire.com)